Idiopathic Parkinson Disease Clinical Trial
Official title:
Quantification of Dopamine Active Transporter (DAT) in Humans: Validation of a New Radiophamaceutical, the [18F] LBT-999
Idiopathic Parkinson's disease (IPD) is a degenerative disease affecting the dopaminergic
system. Clinical symptoms of IPD commonly begin after the loss of at least 40 to 50% of
striatal dopaminergic terminals (specially putaminal terminals).
The Dopamine neuronal transporter (DAT) is a highly expressed protein in the membrane of
presynaptic nigrostriatal dopaminergic terminals. The use of a DAT's radioligand in the
initial stages of the disease would lead to an early detection of nigral cell loss.
Currently, only one DAT's radioligand has obtained marketing authorization in France, the
123I-FPCIT, for use in Single Photon Emission Computed Tomography (SPECT).
Otherwise, the Positron Emission Tomography (PET), a more sensitive technology than SPECT
with higher resolution has become for a few years the new gold standard for visual analysis
and quantification of neurotransmission systems (including the dopaminergic system).
A DAT tracer labelled with Carbon 11 ([11C] PE2l) have been developed and is currently used
as a reference in various research centers.
However, in order to enable a clinical use of this tracer (which currently can't be because
of the too short period of Carbon 11), the unit INSERM U930 "Imaging and Brain" in
collaboration with the CERRP (Center for Studies and Research on Radiopharmaceuticals)
developed a new version of this tracer, labelled with 18-fluor: the [18F] LBT-999.
The main goal of this study is to compare the [18F] LBT-999 uptake between a group of
patients suffering from a Parkinsonien syndrome to a group healthy volunteers.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04202757 -
Intravenous Plasma Treatment for Parkinson's Disease
|
Early Phase 1 | |
| Not yet recruiting |
NCT05103618 -
Effect of Meditation and Controls and Subjects With Parkinson's Disease on Brain Activity Measured by fMRI With FDOPA
|
Phase 2 | |
| Completed |
NCT03700684 -
Voice Treatment for Parkinson's Disease
|
N/A | |
| Completed |
NCT05027620 -
Feasibility of Motor-cognitive Home Training for Parkinson's Disease Using eHealth Technology
|
N/A | |
| Completed |
NCT03652363 -
GDNF in ideopathicParkinsons Disease
|
Phase 2 | |
| Recruiting |
NCT02960464 -
tDCS for Treatment of Depression in Parkinson's Disease
|
N/A | |
| Completed |
NCT05699161 -
Adipose-derived Stromal Vascular Fraction Cells to Treat Parkinson
|
Phase 1/Phase 2 | |
| Completed |
NCT03944785 -
Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide)
|
||
| Completed |
NCT01227265 -
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037)
|
Phase 3 | |
| Terminated |
NCT01215227 -
An Active-Controlled Extension Study to NCT01155466 [P04938] and NCT01227265 [P07037] (P06153)
|
Phase 3 | |
| Withdrawn |
NCT05832775 -
Study to Assess the Safety of MRx0029 or MRx0005 Compared to Placebo, in People With Parkinson's
|
Phase 1 | |
| Active, not recruiting |
NCT02780895 -
Parkinsonian Brain Repair Using Human Stem Cells
|
Phase 1 | |
| Recruiting |
NCT01860794 -
Evaluation of Safety and Tolerability of Fetal Mesencephalic Dopamine Neuronal Precursor Cells for Parkinson's Disease
|
Phase 1/Phase 2 | |
| Completed |
NCT02373072 -
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease
|
Phase 1 | |
| Completed |
NCT02445651 -
Physiological Effects of Nutritional Support in Patients With Parkinson's Disease
|
N/A | |
| Completed |
NCT00437125 -
Study on the Tolerability of Duloxetine in Depressed Patients With Parkinson's Disease
|
Phase 4 | |
| Completed |
NCT02723396 -
Sleep, Awake & Move - Part I
|
||
| Completed |
NCT00599339 -
Transdermal Rotigotine User Surveillance Study
|
||
| Suspended |
NCT05471609 -
Sustained Release Oral Formulation for Treatment of Parkinson's Disease
|
Early Phase 1 | |
| Completed |
NCT00160576 -
Levetiracetam Treatment in Adult Subjects With Parkinson's Disease Experiencing Troublesome Dyskinesias
|
Phase 2 |